These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 28671676)
1. JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells. Wang Q; Chen Q; Zhu L; Chen M; Xu W; Panday S; Wang Z; Li A; Røe OD; Chen R; Wang S; Zhang R; Zhou J Oncogenesis; 2017 Jul; 6(7):e353. PubMed ID: 28671676 [TBL] [Abstract][Full Text] [Related]
2. JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells. Xu W; Chen Q; Wang Q; Sun Y; Wang S; Li A; Xu S; Røe OD; Wang M; Zhang R; Yang L; Zhou J Cell Death Dis; 2014 Dec; 5(12):e1551. PubMed ID: 25476899 [TBL] [Abstract][Full Text] [Related]
3. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells]. Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141 [TBL] [Abstract][Full Text] [Related]
4. LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis. Li M; Zhang YY; Shang J; Xu YD Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4185-4191. PubMed ID: 31173289 [TBL] [Abstract][Full Text] [Related]
5. Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin. Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q Med Oncol; 2015 Apr; 32(4):133. PubMed ID: 25796504 [TBL] [Abstract][Full Text] [Related]
6. RNF185 modulates JWA ubiquitination and promotes gastric cancer metastasis. Qiu D; Wang Q; Wang Z; Chen J; Yan D; Zhou Y; Li A; Zhang R; Wang S; Zhou J Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1552-1561. PubMed ID: 29481911 [TBL] [Abstract][Full Text] [Related]
7. LncRNA DANCR accelerates the development of multidrug resistance of gastric cancer. Xu YD; Shang J; Li M; Zhang YY Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2794-2802. PubMed ID: 31002130 [TBL] [Abstract][Full Text] [Related]
8. JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells. Ma L; Zhu W; Wang Q; Yang F; Qian J; Xu T; Wang S; Zhou J; Shu Y Oncotarget; 2016 Nov; 7(44):71790-71801. PubMed ID: 27708243 [TBL] [Abstract][Full Text] [Related]
9. Decitabine enhances the tumoricidal potential of TRAIL via the epigenetic regulation of death receptor 4 in gastric cancer. Li L; Niu Q; Zhu Y; Fan B; Yang G J Gastrointest Oncol; 2022 Dec; 13(6):2799-2808. PubMed ID: 36636077 [TBL] [Abstract][Full Text] [Related]
10. The expression of TRAIL and its receptors in gastric cancer and the apoptotic effect of rh-TRAIL on SGC7901 cells. Hu JK; Yang K; Li CM; Zhang B; Chen ZX; Chen XZ; Chen JP Oncol Rep; 2009 Mar; 21(3):681-8. PubMed ID: 19212626 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-362-5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein. Wei X; Gao M; Ahmed Y; Gao M; Liu W; Zhang Y; Xie X; Zhao Q; Wang H; Gu K Oncol Lett; 2019 Aug; 18(2):1607-1616. PubMed ID: 31423228 [TBL] [Abstract][Full Text] [Related]
12. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N; Poulaki V; Mitsiades C; Tsokos M Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151 [TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Kim K; Fisher MJ; Xu SQ; el-Deiry WS Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508 [TBL] [Abstract][Full Text] [Related]
14. Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway. Vondálová Blanárová O; Jelínková I; Szöor A; Skender B; Soucek K; Horváth V; Vaculová A; Andera L; Sova P; Szöllosi J; Hofmanová J; Vereb G; Kozubík A Carcinogenesis; 2011 Jan; 32(1):42-51. PubMed ID: 21037225 [TBL] [Abstract][Full Text] [Related]
16. Activation of surrogate death receptor signaling triggers peroxynitrite-dependent execution of cisplatin-resistant cancer cells. Seah S; Low IC; Hirpara JL; Sachaphibulkij K; Kroemer G; Brenner C; Pervaiz S Cell Death Dis; 2015 Oct; 6(10):e1926. PubMed ID: 26492363 [TBL] [Abstract][Full Text] [Related]
17. The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells. Choi E; Kim Y; Kim K Yonsei Med J; 2006 Feb; 47(1):55-62. PubMed ID: 16502485 [TBL] [Abstract][Full Text] [Related]
18. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Kazhdan I; Marciniak RA Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201 [TBL] [Abstract][Full Text] [Related]
19. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma. Kondo K; Yamasaki S; Sugie T; Teratani N; Kan T; Imamura M; Shimada Y Int J Cancer; 2006 Jan; 118(1):230-42. PubMed ID: 16003725 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Zhang XW; Bu P; Liu L; Zhang XZ; Li J Biochem Biophys Res Commun; 2015 Jul; 462(3):227-32. PubMed ID: 25956062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]